4-Methyl-1-(5-methyl-thiazol-4-yl)-pentan-3-one | 261711-30-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-Methyl-1-(5-methyl-thiazol-4-yl)-pentan-3-one
• 英文别名: 4-Methyl-1-(5-methyl-1,3-thiazol-4-yl)pentan-3-one
• CAS: 261711-30-2
• 化学式: C₁₀H₁₅NOS
• 分子量: 197.301
• InChiKey: VCWUKOHXVXMCDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Methyl-1-(5-methyl-thiazol-4-yl)-pentan-3-one 在 sodium hydroxide 、 sodium hydride 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.33h， 生成 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6-isopropyl-6-[2-(5-methyl-thiazol-4-yl)-ethyl]-5,6-dihydro-pyran-2-one
  参考文献：
  名称：

  4-Hydroxy-5,6-dihydropyrones as Inhibitors of HIV Protease:  The Effect of Heterocyclic Substituents at C-6 on Antiviral Potency and Pharmacokinetic Parameters

  摘要：

  Due largely to the emergence of multi-drug-resistant HIV strains, the development of new HIV protease inhibitors remains a high priority for the pharmaceutical industry. Toward this end, we previously identified a 4-hydroxy-5,6-dihydropyrone lead compound (CI-1029, 1) which possesses excellent activity against the protease enzyme, good antiviral efficacy in cellular assays, and promising bioavailability in several animal species. The search for a suitable backup candidate centered on the replacement of the aniline moiety at C-6 with an appropriately substituted heterocyle. In general, this series of heterocyclic inhibitors displayed good activity (in both enzymatic and cellular tests) and-low cellular toxicity; furthermore, several analogues exhibited improved pharmacokinetic parameters in animal models. The compound with the best combination of high potency, low toxicity, and favorable bioavailabilty was (S)-3-(2-tertbutyl-4-hydroxymethy1- 5-methyl-phenylsulfanyl)-4-hydroxy-6-isopropyl-6-(2-thiophen-3-yl-ethyl)-5,6-dihydro-pyran-2-one (13-(S)). This thiophene derivative also exhibited excellent antiviral efficacy against mutant HIV protease and resistant HIV strains. For these reasons, compound 13-(S) was chosen for further preclinical evaluation.

  DOI：

  10.1021/jm0003844
• 作为产物：
  描述：

  5-甲基噻唑-4-甲酸乙酯 在 5percent Pd/BaSO₄ 氢气 、 二异丁基氢化铝 、 potassium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 乙腈 为溶剂， 20.0 ℃ 、220.64 kPa 条件下， 反应 45.5h， 生成 4-Methyl-1-(5-methyl-thiazol-4-yl)-pentan-3-one
  参考文献：
  名称：

  4-Hydroxy-5,6-dihydropyrones as Inhibitors of HIV Protease:  The Effect of Heterocyclic Substituents at C-6 on Antiviral Potency and Pharmacokinetic Parameters

  摘要：

  Due largely to the emergence of multi-drug-resistant HIV strains, the development of new HIV protease inhibitors remains a high priority for the pharmaceutical industry. Toward this end, we previously identified a 4-hydroxy-5,6-dihydropyrone lead compound (CI-1029, 1) which possesses excellent activity against the protease enzyme, good antiviral efficacy in cellular assays, and promising bioavailability in several animal species. The search for a suitable backup candidate centered on the replacement of the aniline moiety at C-6 with an appropriately substituted heterocyle. In general, this series of heterocyclic inhibitors displayed good activity (in both enzymatic and cellular tests) and-low cellular toxicity; furthermore, several analogues exhibited improved pharmacokinetic parameters in animal models. The compound with the best combination of high potency, low toxicity, and favorable bioavailabilty was (S)-3-(2-tertbutyl-4-hydroxymethy1- 5-methyl-phenylsulfanyl)-4-hydroxy-6-isopropyl-6-(2-thiophen-3-yl-ethyl)-5,6-dihydro-pyran-2-one (13-(S)). This thiophene derivative also exhibited excellent antiviral efficacy against mutant HIV protease and resistant HIV strains. For these reasons, compound 13-(S) was chosen for further preclinical evaluation.

  DOI：

  10.1021/jm0003844

文献信息

• MCL-1 INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20190352271A1

  公开（公告）日：2019-11-21

  The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

  本公开涉及通常用于治疗癌症的化合物和药物组合物。
• HIV protease inhibitors
  申请人：——

  公开号：US20040106606A1

  公开（公告）日：2004-06-03

  The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.

  本发明涉及一种新颖的具有改进药理学性质的带有连接杂环的二氢吡喃并具有强烈抑制HIV天冬氨酸蛋白酶以阻止HIV感染性的药物。这些二氢吡喃可用于开发治疗病毒感染和疾病，包括艾滋病的治疗方案。本发明还涉及二氢吡喃的合成方法以及用于制备最终化合物的中间体。
• MCL-1 inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US10988451B2

  公开（公告）日：2021-04-27

  The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

  本公开内容一般涉及可用于治疗癌症方法的化合物和药物组合物。
• HIV PROTEASE INHIBITORS
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1112269A2

  公开（公告）日：2001-07-04
• US6528510B1
  申请人：——

  公开号：US6528510B1

  公开（公告）日：2003-03-04